A Phase I Trial of Bevacizumab and Bortezomib in Patients With Advanced Malignancy.
Latest Information Update: 19 Feb 2013
At a glance
- Drugs Bevacizumab (Primary) ; Bortezomib (Primary)
- Indications Cancer
- Focus Adverse reactions
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 22 Nov 2011 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 26 Oct 2011 Planned End Date changed from 1 Jan 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.